Navigation Links
CareFusion Reports Fourth Quarter and Fiscal 2011 Results
Date:8/8/2011

P financial measures provides useful information to investors regarding CareFusion's financial condition and results of operations is included as Exhibit 99.3 to CareFusion's report on Form 8-K filed with the Securities and Exchange Commission on Aug. 8, 2011.

Cautions Concerning Forward-looking StatementsThe CareFusion news release and the information contained herein contains forward-looking statements addressing expectations, prospects, estimates and other matters that are dependent upon future events or developments. The matters discussed in these forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, anticipated or implied. The most significant of these uncertainties are described in CareFusion's Form 10-K, Form 10-Q and Form 8-K reports (including all amendments to those reports) and exhibits to those reports, and include (but are not limited to) the following: we may be unable to effectively enhance our existing products or introduce and market new products or may fail to keep pace with advances in technology; we are subject to complex and costly regulation; cost containment efforts of our customers, purchasing groups, third-party payers and governmental organizations could adversely affect our sales and profitability; current economic conditions have and may continue to adversely affect our results of operations and financial condition; we may be unable to realize any benefit from our cost reduction and restructuring efforts and our profitability may be hurt or our business otherwise might be adversely affected; we may be unable to protect our intellectual property rights or may infringe on the intellectual property rights of others; defects or failures associated with our products and/or our quality system could lead to the filing of adverse event reports, recalls or safety alerts and negative publicity and could subject us to regulatory actions; we are currently
'/>"/>

SOURCE CareFusion Corp.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related medicine technology :

1. CareFusion and ResMed Announce Distribution Agreement for U.S. Hospital Market
2. CareFusion Will Host an Earnings Conference Call on Aug. 8 to Discuss the Results for the Fourth Quarter and Fiscal 2011
3. CareFusion to Acquire Pharmacy Automation Innovator Rowa
4. CareFusion Reports Third Quarter Rise in Revenue, Earnings
5. CareFusion Will Host an Earnings Conference Call on May 5 to Discuss the Results for the Third Quarter Fiscal 2011
6. CareFusion Acquires Technology for Sorting and Managing Dangerous Pharmaceutical Waste
7. CareFusion Announces Departure of Chief Operating Officer
8. CareFusion Completes Sale of Onsite Services Instrument Management and Repair Business
9. CareFusion Launches Innovative Vertebral Balloon That Gives Surgeons More Options to Treat Spinal Fractures
10. CareFusion Launches Compact Ventilator to Enhance Home-Based Patient Mobility
11. CareFusion Appoints Carlos M. Nunez, M.D. as Chief Medical Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... PALO ALTO, Calif. , Aug. 1, 2014 ... today announced a partnership to expand awareness of proper ... the CFChef Shares program. CFChef Shares will run from ... AbbVie,s CFChef program – an online resource for CF ... a healthy diet by submitting recipes to the ...
(Date:8/1/2014)... Mass. , Aug. 1, 2014  NxStage Medical, Inc. ... dialysis products, today announced that Jeffrey H. Burbank , ... Officer, will present at the 34 th Annual Canaccord ... Boston, MA , on Wednesday, August 13 th ... will be made available at http://ir.nxstage.com/ .  ...
(Date:8/1/2014)... Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) announced ... report its second quarter 2014 financial results on Monday, ... J. Joseph Kim and CFO Peter ... corporate update, and participate in a live Q&A with ... VGX-3100, Inovio,s immune therapy targeting pre-cancers and cancers associated ...
Breaking Medicine Technology:AbbVie and Cystic Fibrosis Research, Inc. (CFRI) Team Up to Raise Awareness of the Nutritional Needs of CF Patients through the CFChef Shares Program 2AbbVie and Cystic Fibrosis Research, Inc. (CFRI) Team Up to Raise Awareness of the Nutritional Needs of CF Patients through the CFChef Shares Program 3NxStage to Present at the 34th Annual Canaccord Genuity Growth Conference 2Inovio Pharmaceuticals to Host Second Quarter 2014 Financial Results Call on August 11, 2014 2Inovio Pharmaceuticals to Host Second Quarter 2014 Financial Results Call on August 11, 2014 3
(Date:8/1/2014)... The European gas chromatography systems report defines and segments the ... The gas chromatography systems market in Europe is valued at ... around $247.6 million by 2018, at a CAGR of 5.3% ... the European gas chromatography systems market, to get an idea ... of the segmentation of gas chromatography systems market in the ...
(Date:8/1/2014)... 2014 The North America Sports Drink Market ... America, with analysis and forecast of revenue. The Sports Drink ... $5,021.9 million in 2012 to $6,243 million by 2018, at ... through the TOC of the North America Sports Drink market ... This also provides a glimpse of the segmentation in the ...
(Date:8/1/2014)... Gerontological Society of America (GSA) the ... aging has chosen Carole B. Lewis, PT, DPT, ... recipient of the Excellence in Rehabilitation of Aging Persons ... acknowledge outstanding contributions in the field of rehabilitation. The ... or patient care, or publications that may include scholarly ...
(Date:8/1/2014)... Home Care Assistance of Cincinnati , ... to be recognized as a 2014 Best of Home Care ... care providers who rank in the top 50th percentile in ... interviews conducted by Home Care Pulse. , “The Best ... the best of the best!” says Home Care Pulse Founder ...
(Date:8/1/2014)... 01, 2014 With fast food restaurants on ... convenience of processed, microwavable dinners, it is no wonder that ... offer patients a mere quick fix for shedding this dangerous ... part of the country, get slimmer and healthier for the ... the tools and education on how to avoid obesity ...
Breaking Medicine News(10 mins):Health News:European Gas Chromatography (GC) Systems Market is Expected to Reach $247.6 Million in 2018 - New Report by MicroMarket Monitor 2Health News:European Gas Chromatography (GC) Systems Market is Expected to Reach $247.6 Million in 2018 - New Report by MicroMarket Monitor 3Health News:European Gas Chromatography (GC) Systems Market is Expected to Reach $247.6 Million in 2018 - New Report by MicroMarket Monitor 4Health News:North America Sports Drinks Market is Expected to Reach $6,243 Million in 2018 - New Report by MicroMarket Monitor 2Health News:North America Sports Drinks Market is Expected to Reach $6,243 Million in 2018 - New Report by MicroMarket Monitor 3Health News:North America Sports Drinks Market is Expected to Reach $6,243 Million in 2018 - New Report by MicroMarket Monitor 4Health News:Lewis to receive GSA's 2014 Excellence in Rehabilitation of Aging Persons Award 2Health News:Cincinnati Senior Care Company Receives 2014 Best of Home Care® Employer of Choice Award 2Health News:Diet Doc Medical Weight Loss Programs Announces Diet Plans That Melt Excess Fat Rapidly While Teaching Patients How to Avoid Obesity 2Health News:Diet Doc Medical Weight Loss Programs Announces Diet Plans That Melt Excess Fat Rapidly While Teaching Patients How to Avoid Obesity 3
... cancer that is being developed is the use of ... normal cells unharmed. These viruses are known as virotherapeutics. ... Jennerex Biotherapeutics, San Francisco, have described the development of ... and rabbits. , After selecting a highly potent strain ...
... in cancer incidence and mortality are well documented. ... is a factor in cancer disparities, other factors ... genetics, hormonal status, lifestyle and behavior, screening policies, ... response to therapy, and post-therapeutic surveillance. , ...
... used to cut down on bleeding during cardiac surgery , , ... Drug Administration on Thursday said it will review the safety ... trial was stopped early due to an increase in deaths ... first approved by the FDA in 1993, is typically used ...
... Oct. 25 /PRNewswire-FirstCall/ - SXC Health Solutions Inc.,(NASDAQ: ... Glenn, Chairman and,Chief Executive Officer, will host a conference ... to discuss the Company,s fiscal 2007 third quarter,financial results. ... at 6:00 a.m. ET that same day. All ...
... During the Second Fiscal ... Quarter ... Reiterates Fiscal 2008 Guidance, MOUNTAIN VIEW, Calif., Oct. 25 Pharsight,Corporation (OTC ... clinical drug development, today,announced financial results for its second quarter of fiscal 2008, ...
... with Osiris on a Phase II Trial to Evaluate ... , New York, NY October 25, ... a partnership with Osiris Therapeutics, Inc. (NASDAQ:OSIR) to support ... cell therapy product, to preserve and regenerate insulin-producing cells ...
Cached Medicine News:Health News:FDA to Review Clotting Drug After Trial Suggests Death Risk 2Health News:FDA to Review Clotting Drug After Trial Suggests Death Risk 3Health News:FDA to Review Clotting Drug After Trial Suggests Death Risk 4Health News:SXC Health Solutions to Host Fiscal 2007 Third Quarter Financial Results Conference Call 2Health News:Pharsight Achieves $7.3 Million in Quarterly Revenue 2Health News:Pharsight Achieves $7.3 Million in Quarterly Revenue 3Health News:Pharsight Achieves $7.3 Million in Quarterly Revenue 4Health News:Pharsight Achieves $7.3 Million in Quarterly Revenue 5Health News:Pharsight Achieves $7.3 Million in Quarterly Revenue 6Health News:Pharsight Achieves $7.3 Million in Quarterly Revenue 7Health News:Pharsight Achieves $7.3 Million in Quarterly Revenue 8Health News:Pharsight Achieves $7.3 Million in Quarterly Revenue 9Health News:Pharsight Achieves $7.3 Million in Quarterly Revenue 10Health News:Pharsight Achieves $7.3 Million in Quarterly Revenue 11Health News:Pharsight Achieves $7.3 Million in Quarterly Revenue 12Health News:JDRF Partners with Osiris to evaluate an immunomodulatory cell therapy product for type 1 diabetes 2
... Complete includes the nutrients used in the ... Antioxidant Supplement Trial (LAST), which suggested no ... in a one year period. Macula Complete ... in peer-reviewed studies to support the mitochondria, ...
... Soft Gel Lutein patented formula is based ... PreserVision® AREDS formula, with the beta-carotene substituted ... is a carotenoid found in dark leafy ... highly concentrated in the macula, the part ...
... & Lomb PreserVision® AREDS formula is the ... supplement clinically proven effective in the 10-year ... Eye Disease Study (AREDS). , PreserVision® AREDS ... supplement with the antioxidant vitamins A, C, ...
... scientific formulation that provides the foundation ... basic eye-specific nutritional support. All ingredients ... standards, when applicable. ScienceBased Health formulations ... maximum bioavailability, and are free of ...
Medicine Products: